These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32699982)

  • 1. Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1.
    Paubelle E; Plesa A; Hayette S; Elhamri M; Zylbersztejn F; Hermine O; Salles G; Thomas X
    Oncol Ther; 2019 Dec; 7(2):121-130. PubMed ID: 32699982
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Nguyen CH; Grandits AM; Vassiliou GS; Staber PB; Heller G; Wieser R
    Biomedicines; 2020 Sep; 8(10):. PubMed ID: 32998330
    [No Abstract]   [Full Text] [Related]  

  • 3. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
    Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
    Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Nguyen CH; Grandits AM; Purton LE; Sill H; Wieser R
    Cell Cycle; 2020 Oct; 19(20):2573-2588. PubMed ID: 32900260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive].
    Duan WB; Gong LZ; Jia JS; Zhu HH; Zhao XS; Jiang Q; Zhao T; Wang J; Qin YZ; Huang XJ; Jiang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):990-995. PubMed ID: 29263470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
    Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
    J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation.
    van Gils N; Verhagen HJMP; Smit L
    Exp Hematol; 2017 Aug; 52():12-23. PubMed ID: 28456748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
    Belhabri A; Thomas X; Wattel E; Chelghoum Y; Anglaret B; Vekhoff A; Reman O; Dombret H; Dhedin N; Michallet M; Fière D; Archimbaud E
    Hematol J; 2002; 3(1):49-55. PubMed ID: 11960396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
    Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
    J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups.
    Bassan R; Chiodini B; Lerede T; Giussani U; Oldani E; Buelli M; Rossi A; Viero P; Rambaldi A; Barbui T
    Hematol J; 2002; 3(4):193-200. PubMed ID: 12189565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
    Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
    Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomodulatory Treatment With Azacitidine, All-
    Klobuch S; Steinberg T; Bruni E; Mirbeth C; Heilmeier B; Ghibelli L; Herr W; Reichle A; Thomas S
    Front Pharmacol; 2018; 9():1380. PubMed ID: 30542286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment.
    Su M; Alonso S; Jones JW; Yu J; Kane MA; Jones RJ; Ghiaur G
    PLoS One; 2015; 10(6):e0127790. PubMed ID: 26047326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship.
    Agadir A; Cornic M; Lefebvre P; Gourmel B; Jérôme M; Degos L; Fenaux P; Chomienne C
    J Clin Oncol; 1995 Oct; 13(10):2517-23. PubMed ID: 7595702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation.
    Iriyama N; Yuan B; Hatta Y; Takagi N; Takei M
    Cancer Cell Int; 2016; 16():37. PubMed ID: 27182202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].
    Meng YS; Ma XX; Meng XQ; Wei R; Liu W; Ai GW; Zhang YX
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3406-10. PubMed ID: 18476539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-trans retinoic acid as a single agent induces complete remission in a patient with acute leukemia of M2a subtype.
    Chen Z; Wang Y; Wang W; Gong J; Xue Y
    Chin Med J (Engl); 2002 Jan; 115(1):58-61. PubMed ID: 11930660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.
    Ustün C; Beksac M; Dalva K; Koc H; Konuk N; Ilhan O; Ozcan M; Topcuoglu P; Sertkaya D; Hayran M
    Med Oncol; 2002; 19(1):59-67. PubMed ID: 12025892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
    Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
    Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
    Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
    Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.